NKTX Stock Summary and Trading Ideas (Nkarta | NASDAQ:NKTX)

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Nkarta trades on the NASDAQ stock market under the symbol NKTX.

As of March 3, 2025, NKTX stock price declined to $1.65 with 385,178 million shares trading.

NKTX has a beta of 1.88, meaning it tends to be more sensitive to market movements. NKTX has a correlation of 0.08 to the broad based SPY ETF.

NKTX has a market cap of $116.42 million. This is considered a Micro Cap stock.

In the last 3 years, NKTX traded as high as $20.35 and as low as $1.28.

The top ETF exchange traded funds that NKTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

NKTX has underperformed the market in the last year with a price return of -84.8% while the SPY ETF gained +17.9%. NKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.8% and -25.3%, respectively, while the SPY returned -1.2% and -3.3%, respectively.

NKTX support price is $1.68 and resistance is $1.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTX shares will trade within this expected range on the day.